At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 204 enrolled
Drug / intervention
ARO-ANG3 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
In Brief
A Phase 2 clinical trial evaluating ARO-ANG3 and Placebo for Mixed Dyslipidemia. Completed, enrolled 204 participants across 24 sites in 4 countries.
Detailed Summary
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMixed Dyslipidemia
CountriesAustralia, Canada, New Zealand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartJun 2021
Primary CompletionAug 2022
Study CompletionSep 2024
TodayJul 2026
First PostedApr 6, 2021
Enrollment StartJun 28, 2021
Primary CompletionAug 30, 2022
Study CompletionSep 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.2 years ago
Interventions
ARO-ANG3drug
ARO-ANG3 Injection
Placebodrug
Sterile Normal Saline (0.9% NaCl)